GlassScriptPhysician profile
Salil Mangi
NPI 1881693695
$33,267.25
in general payments reported to CMS, 2019-2025
21 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,091 · 2020: $3,569 · 2021: $3,899 · 2022: $4,568 · 2023: $2,851 · 2024: $12K · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $2,260 · Travel and Lodging: $886 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,976.25 |
| Food and Beverage | $2,260.41 |
| Travel and Lodging | $886.18 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $19,992.89 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,388.01 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $3,145.00 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $717.50 | 2020 | |
| Fresenius USA Marketing, INC. | $315.30 | 2019-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $272.13 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $234.52 | 2023-2025 | Terlivaz |
| Amgen INC. | $170.18 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $162.77 | 2022-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $145.17 | 2024 | |
| Akebia Therapeutics INC | $137.45 | 2019-2022 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $124.99 | 2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $115.43 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $59.22 | 2022-2023 | Jesduvroq, Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $43.61 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $32.39 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.44 | 2024 | |
| Novo Nordisk INC | $22.86 | 2024 | Rivfloza |
| Abbvie INC. | $20.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salil Mangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.